Advertisement

The Clinical and Experimental Use of Monoclonal Antibodies to the IL-2 Receptor

  • Peter L. Amlot
Part of the Medical Intelligence Unit book series (MIU.LANDES)

Abstract

The immune system is economical with the number of antigen specific cells available to counter intermittent and infrequent antigenic challenges from infectious organisms and relies upon rapid cellular expansion in times of need. Cellular recognition of specific antigens leads to rapid proliferation of antigen specific cells and this process is called clonal expansion. Along with this clonal expansion there is also a diversification of potential effector cells and mechanisms. The response to antigen exposure is thus characterised by amplification. Initiating events in this amplification make appropriate targets for manipulating the immune system in a specific manner. Identification of interleukin 2 (IL-2) as an important T-cell growth factor1 was followed by the development of a monoclonal antibody (MoAb), anti-Tac, recognizing the IL-2 receptor (IL-2R).2 The early involvement of IL-2 in T-cell proliferation together with the acquisition of a MoAb that interfered with the function of IL-2 gave rise to hope that specific manipulation of the immune system was achievable. It has been said that the interaction between IL-2 and IL-2 receptors determines the magnitude and duration of the immune response. Either blocking of IL-2R or eliminating cells expressing IL-2R could be beneficial in suppressing unwanted immune responses.

Keywords

Graft Versus Host Disease Mixed Lymphocyte Reaction Acute Graft Versus Host Disease Chronic Graft Versus Host Disease Receptor Monoclonal Antibody 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    Morgan DA, Ruscetti FW and Gallo RC. Selective in vitro growth of T-lymphocytes from normal human bone marrow. Science 1976; 193: 1007–1008.PubMedCrossRefGoogle Scholar
  2. 2.
    Leonard WJ, Depper JM, Uchiyama T, Smith KA, Waldmann TA and Greene WC. A monoclonal antibody that appears to recognize the receptor for human T-cell growth factor; partial characterization of the receptor. Nature 1982; 300: 267–269.PubMedCrossRefGoogle Scholar
  3. 3.
    Jenkinson EJ, Kingston R and Owen JJ. Importance of IL-2 receptors in intrathymic generation of cells expressing T-cell receptors. Nature 1987; 329: 160–162.PubMedCrossRefGoogle Scholar
  4. 4.
    Tanaka T, Takeuchi Y, Shiohara T et al. In utero treatment with monoclonal antibody to IL-2 receptor beta-chain completely abrogates development of Thy-1+ dendritic epidermal cells. Int Immunol 1992; 4: 487–491.PubMedCrossRefGoogle Scholar
  5. 5.
    Hefeneider S, Conlon P, Henney C and Gillis S. In vivo interleukin 2 administration augments the generation of alloreactive cytolytic T lymphocytes and resident natural killer cells. J Immunol 1983; 130: 222–227.PubMedGoogle Scholar
  6. 6.
    Handa K, Suzuki R, Matsui H, Shimizu Y and Kumagai K. Natural killer (NK) cells as a responder to interleukin-2 (rIL-2). II. rIL-2-induce interferon gamma production. J Immunol 1983; 130: 988–992.Google Scholar
  7. 7.
    Mule JJ, Shu S and Rosenberg SA. The anti-tumour efficacy of lymphokine-activated killer cells and recombinant interleukin 2 in vivo. J Immunol 1984; 135: 646–652.Google Scholar
  8. 8.
    Rosenstein M, Yron I, Kaufmann Y and Rosenberg SA. Lymphokine activated killer cells: lysis of fresh syngeneic NK-resistant murine tumor cells by lymphocytes cultured in interleukin-2. Cancer Res 1984; 44: 1946–1953.PubMedGoogle Scholar
  9. 9.
    Burdach S, Shatsky M, Wagenhorst B and Levitt L. Receptor specific modulation of myelopoiesis by recombinant DNA-derived IL-2. J Immunol 1987; 139: 452–458.PubMedGoogle Scholar
  10. 10.
    Uchiyama T, Nelson DL, Fleisher TA and Waldmann TA. A monoclonal antibody (anti-Tac) reactive with activated and functionally mature human T cells. II. Expression of Tac antigen on activated cytotoxic killer T cells, suppressor cells, and on one of two types of helper T cells. J Immunol 1981; 126: 1398–1403.PubMedGoogle Scholar
  11. 11.
    Hatakeyama M, Tsudo M, Minamoto S et al. Interleukin-2 receptor β chain gene: Generation of three receptor forms by cloned human α and β chain cDNA’s. Science 1989; 244: 551–556.PubMedCrossRefGoogle Scholar
  12. 12.
    Tsudo M, Karasuyama H, Kitamura F, Nagakaka Y, Tanaka T and Miyasaka M. The IL-2 receptor β chain (p70): Ligand binding ability of the cDNA-encoding membrane and secreted forms. J Immunol 1990; 145: 599–606.PubMedGoogle Scholar
  13. 13.
    Minamoto S, Mori H, Hatakeyama M et al. Characterisation of the heterodimeric complex of human IL-2 receptor αβ chains reconstituted in a mouse fibroblast cell line, L929. J Immunol 1990; 145: 2177–2182.PubMedGoogle Scholar
  14. 14.
    Voss SD, Robb RJ, Weil-Hillman G et al. Increased expression of the interleukin 2 (IL-2) receptor β chain (p70) on CD56+ natural killer cells after in vivo IL-2 therapy: p70 expression does not alone predict the level of intermediate affinity IL-2 binding. J Exp Med 1990; 172: 1101–1114.PubMedCrossRefGoogle Scholar
  15. 15.
    Takeshita T, Ohtani K, Asao H, Kumaki S, Nakamura M and Sugamura K. An associated molecule, p64, with IL-2 receptor β chain. J Immunol 1992; 148: 2154–2158.PubMedGoogle Scholar
  16. 16.
    Takeshita T, Asao H, Suzuki J and Sugamura K. An associated molecule, p64, with high affinity IL-2 receptor. Int Immunol 1990; 2: 477–480.PubMedCrossRefGoogle Scholar
  17. 17.
    Taniguchi T, Matsui H, Fujita T et al. Structure and expression of a cloned cDNA for human interleukin-2. Nature 1983; 302: 305–310.PubMedCrossRefGoogle Scholar
  18. 18.
    Nakamura Y, Russell SM, Mess SA et al. Heterodimerization of the IL-2 receptor beta-and gamma-chain cytoplasmic domains is required for signaling. Nature 1994; 369: 330–333.PubMedCrossRefGoogle Scholar
  19. 19.
    Nelson BH, Lord JD and Greenberg PD. Cytoplasmic domains of the interleukin-2 receptor beta and gamma chains mediate the signal for T-cell proliferation. Nature 1994; 369: 333–336.PubMedCrossRefGoogle Scholar
  20. 20.
    Rubin LA, Jay G and Nelson DL. The released interleukin-2 receptor binds interleukin-2 efficiently. J Immunol 1986; 137: 3841–3844.PubMedGoogle Scholar
  21. 21.
    Siegel JP, Sharon M, Smith PL and Leonard WJ. The IL-2 receptor β chain (p70):role in mediating signals for LAK, NK and proliferative activities. Science 1987; 238: 75–78.PubMedCrossRefGoogle Scholar
  22. 22.
    Audrain M, Boeffard F, Soulillou JP and Jacques Y. Synergistic action of monoclonal antibodies directed at p55 and p75 chains of the human IL-2-receptor. J Immunol 1991; 146: 884–892.PubMedGoogle Scholar
  23. 23.
    Bamford RN, Grant AJ, Burton JD et al. The interleukin (IL) 2 receptor beta chain is shared by IL-2 and a cytokine, provisionally designated IL-T, that stimulates T-cell proliferation and the induction of lymphokine-activated killer cells. Proc Natl Acad Sci USA 1994; 91: 4940–4944.PubMedCrossRefGoogle Scholar
  24. 24.
    Giri JG, Ahdieh M, Eisenman J et al. Utilization of the beta and gamma chains of the IL-2 receptor by the novel cytokine IL-15. EMBO J 1994; 13: 2822–2830.PubMedGoogle Scholar
  25. 25.
    Grabstein KH, Eisenman J, Shanebeck K et al. Cloning of at cell growth factor that interacts with the β chain of the interleukin-2 receptor. Science 1994; 264: 965–968.PubMedCrossRefGoogle Scholar
  26. 26.
    Takeshita T, Asao H, Ohtani K et al. Cloning of the gamma chain of the human IL-2 receptor. Science 1992; 257: 379–382.PubMedCrossRefGoogle Scholar
  27. 27.
    Kondo M, Takeshita T, Ishii N et al. Sharing of the interleukin-2 (IL-2) receptor gamma chain between receptors for IL-2 and IL-4 [see comments]. Science 1993; 262: 1874–1877.PubMedCrossRefGoogle Scholar
  28. 28.
    Russell SM, Keegan AD, Harada N et al. Interleukin-2 receptor gamma chain: a functional component of the interleukin-4 receptor [see comments]. Science 1993; 262: 1880–1883.PubMedCrossRefGoogle Scholar
  29. 29.
    Noguchi M, Nakamura Y, Russell SM et al. Interleukin-2 receptor γ chain: a functional component of the interleukin-7 receptor. Science 1993; 262: 1877–1880.PubMedCrossRefGoogle Scholar
  30. 30.
    Kondo M, Takeshita T, Higuchi M et al. Functional participation of the IL-2 receptor gamma chain in IL-7 receptor complexes. Science 1994; 263: 1453–1454.PubMedCrossRefGoogle Scholar
  31. 31.
    Fernandez-Botran R, Sanders VM and Vitetta ES. Interactions between receptors for interleukin 2 and interleukin 4 on lines of helper T cells (HT-2) and B lymphoma cells (BCL1). J Exp Med 1989; 169: 379–391.PubMedCrossRefGoogle Scholar
  32. 32.
    Martinez OM, Gibbons RS, Garovoy MR and Aronson FR. IL-4 inhibits IL-2 receptor expression and IL-2-dependent proliferation of human T cells. J Immunol 1990; 144: 2211–2215.PubMedGoogle Scholar
  33. 33.
    Lee HK, Xia X and Choi YS. IL-4 blocks the up-regulation of IL-2 receptors induced by IL-2 in normal human B cells. J Immunol 1990; 144: 3431–3436.PubMedGoogle Scholar
  34. 34.
    Defrance T, Vanbervliet B, Aubry JP and Banchereau J. Interleukin 4 inhibits the proliferation but not the differentiation of activated human B cells in response to interleukin 2. J Exp Med 1988; 168: 1321–1337.PubMedCrossRefGoogle Scholar
  35. 35.
    Vazquez A, Mills S and Maizel A. Modulation of IL-2-induced human B cell proliferation in the presence of human 50-kDa B cell growth factor and IL-4. J Immunol 1989; 142: 94–99.PubMedGoogle Scholar
  36. 36.
    Migliorati G, Cardinali L and Riccardi C. Effect of interleukin-4 on interleukin-2-dependent generation of natural killer cells. Cell Immunol 1991; 136: 194–207.PubMedCrossRefGoogle Scholar
  37. 37.
    Muegge K, Vila MP and Durum SK. Interleukin-7:A cofactor for V(D)J rearrangement of the T cell receptor β chain. Science 1993; 261: 93–95.PubMedCrossRefGoogle Scholar
  38. 38.
    Watson JD, Morrissey PJ, Namen AE, Conlon PJ and Widmer MB. Effect of IL-7 on the growth of fetal thymocytes in culture. J Immunol 1989; 143: 1215–1222.PubMedGoogle Scholar
  39. 39.
    Murray R, Suda T, Wrighton N, Lee F and Zlotnik A. IL-7 is a growth and maintenance factor for mature and immature thymocyte subsets. Int Immunol 1989; 1: 526–531.PubMedCrossRefGoogle Scholar
  40. 40.
    Uckun FM. Interleukin 7 receptor engagement stimulates tyrosine phosphorylation, inositol phospholipid turnover, proliferation, and selective differentiation to the CD4 lineage by human fetal thymocytes. Proc Natl Acad Sci USA 1991; 88: 6323–6327.PubMedCrossRefGoogle Scholar
  41. 41.
    Chazen GD. Interleukin 7 is a T-cell growth factor. Proc Natl Acad Sci USA 1989; 86: 5923–5927.PubMedCrossRefGoogle Scholar
  42. 42.
    Londei M, Verhoef A, Hawrylowicz C, Groves J, DeBerardinis P and Feldmann M. Interleukin 7 is a growth factor for mature human T cells. Eur J Immunol 1990; 20: 425–428.PubMedCrossRefGoogle Scholar
  43. 43.
    Morrissey PJ. Recombinant interleukin 7, pre-B cell growth factor, has costimulatory activity on purified mature T cells. J Exp Med 1989; 169: 707–716.PubMedCrossRefGoogle Scholar
  44. 44.
    Carding SR, Hayday AC and Bottomly K. Cytokines in T-cell development. Immunol Today 1991; 12: 239–245.PubMedCrossRefGoogle Scholar
  45. 45.
    Foxwell BM, Willcocks JL, Taylor-Fishwick DA, Kulig K, Ryffel B and Londei M. Inhibition of activation-induced changes in the structure of the T cell interleukin-7 receptor by cyclosporin A and FK506. Eur J Immunol 1993; 23: 85–89.PubMedCrossRefGoogle Scholar
  46. 46.
    Noguchi M, Yi H, Rosenblatt HM et al. Interleukin-2 receptor ψ chain mutation results in X-linked severe combined immunodeficiency in humans. Cell 1993; 73: 147–157.PubMedCrossRefGoogle Scholar
  47. 47.
    Saltzman EM, Thorn RR and Casnellie JE. Activation of a tyrosine protein kinase is an early event in the stimulation of T lymphocytes by interleukin-2. J Biol Chem 1988; 263: 6956–6959.PubMedGoogle Scholar
  48. 48.
    Cantrell DA and Smith KA. The interleukin-2 T-cell system:a new cell growth model. Science 1984; 224: 1312–1316.PubMedCrossRefGoogle Scholar
  49. 49.
    Minami Y, Kono T, Miyazaki T and Taniguchi T. The IL-2 receptor complex:its structure, function, and target genes. [Review]. Ann Rev Immunol 1993; 11: 245–268.CrossRefGoogle Scholar
  50. 50.
    Roussel MF, Cleveland JL, Shurtleff SA and Sherr CJ. Myc rescue of a mutant CSF-1 receptor impaired in mitogenic signaling. Nature 1991; 353: 361–363.PubMedCrossRefGoogle Scholar
  51. 51.
    Schorle H, Holtschke T, Hunig T, Schimpl A and Horak I. Development and function of T cells in mice rendered interleukin-2 deficient by gene targeting. Nature 1991; 352: 621–624.PubMedCrossRefGoogle Scholar
  52. 52.
    Kuhn R, Rajewsky K and Muller W. Generation and analysis of interleukin-4 deficient mice. Science 1991; 254: 707–710.PubMedCrossRefGoogle Scholar
  53. 53.
    Kopf M, Le Gros G, Bachmann M, Lamers MC, Bluethmann H and Kohler G. Disruption of the murine IL-4 gene blocks the Th2 cytokine responses. Nature 1993; 362: 245–247.PubMedCrossRefGoogle Scholar
  54. 54.
    Sadlack B, Merz H, Schorle H, Schimpl A, Feller AC and Horak I. Ulcerative colitis-like disease in mice with a disrupted interleukin-2 gene. Cell 1993; 75: 253–261.PubMedCrossRefGoogle Scholar
  55. 55.
    DiSanto JP, Keever CA, Small TN, Nichols GL, O’Reilly RJ and Flomenberg N. Absence of interleukin 2 production in a severe combined immunodeficiency disease syndrome with T cells. J Exp Med 1990; 171: 1697–1704.PubMedCrossRefGoogle Scholar
  56. 56.
    Katsuki M, Kimura M, Ohta M et al. Lymphocyte infiltration into cerebellum in transgenic mice carrying human IL-2 gene. Int Immunol 1989; 1: 214–218.PubMedCrossRefGoogle Scholar
  57. 57.
    Ishida Y, Nishi M, Taguchi O et al. Effects of the deregulated expression of human interleukin-2 in transgenic mice. Int Immunol 1989; 1: 113–120.PubMedCrossRefGoogle Scholar
  58. 58.
    Boulay JL and Paul WE. The interleukin-4-related lymphokines and their binding to hematopoietin receptors. J Biol Chem 1992; 267: 20525–20528.PubMedGoogle Scholar
  59. 59.
    Bazan JF. Structural design and molecular evolution of a cytokine receptor superfamily. Proc Natl Acad Sci USA 1990; 87: 6934–6938.PubMedCrossRefGoogle Scholar
  60. 60.
    Kanakura Y, Sugahara H, Mitsui H et al. Functional expression of interleukin 2 receptor in a human factor-dependent megakaryoblastic leukemia cell line: Evidence that granulocyte-macrophage colonystimulating factor inhibits interleukin 2 binding to its receptor. Cancer Res 1993; 53: 675–680.PubMedGoogle Scholar
  61. 61.
    Cao X, Kozak CA, Liu YJ, Noguchi M, O’Connell E and Leonard WJ. Characterization of cDNAs encoding the murine interleukin 2 receptor (IL-2R) gamma chain: chromosomal mapping and tissue specificity of IL-2R gamma chain expression. Proc Nad Acad Sci USA 1993; 90: 8464–8468.CrossRefGoogle Scholar
  62. 62.
    Sudo T. Expression and function of the interleukin 7 receptor in murine lymphocytes. Proc Nad Acad Sci USA 1993; 90: 9125–9129.CrossRefGoogle Scholar
  63. 63.
    Grabstein KH, Waldschmidt TJ, Finkelman FD et al. Inhibition of murine B and T lymphopoiesis in vivo by an anti-interleukin 7 monoclonal antibody. J Exp Med 1993; 178: 257–264.PubMedCrossRefGoogle Scholar
  64. 64.
    Amlot PL, Rawlings E, Tahami F and Chinn D. Concordant and discordant expression of activation antigens on human T cells (TCRab) from umbilical cord, adult blood and lymphoid tissue measured by two colour flow cytometry. Clin Exp Immunol 1995; (in press).Google Scholar
  65. 65.
    Niguma T, Sakagami K, Kawamura T et al. Expression of the interleukin 2 receptor beta chain (p75) in renal transplantation—applicability of anti-interleukin-2 receptor beta chain monoclonal antibody. Transplantation 1991; 52: 296–302.PubMedCrossRefGoogle Scholar
  66. 66.
    Ishii N, Takeshita T, Kimura Y et al. Expression of the IL-2 receptor γ chain on various populations in human peripheral blood. Int Immunol 1994; 6: 1273–1277.PubMedCrossRefGoogle Scholar
  67. 67.
    Plaisance S, Rubinstein E, Alileche A et al. Expression of the interleukin-2 receptor on human fibroblasts and its biological significance. Int Immunol 1992; 4: 739–746.PubMedCrossRefGoogle Scholar
  68. 68.
    Caux C, Massacrier C, Vanbervliet B et al. Activation of human dendritic cells through CD40 cross-linking. J Exp Med 1994; 180: 1263.PubMedCrossRefGoogle Scholar
  69. 69.
    Kupiec-Weglinski JW, Diamantstein T and Tilney NL. Interleukin 2 receptor-targeted therapy-rationale and applications in organ transplantation. Transplantation 1988; 46: 785–792.PubMedCrossRefGoogle Scholar
  70. 70.
    Tellides G, Dallman MJ and Morris PJ. Synergistic interaction of cyclosporine A with interleukin 2 receptor monoclonal antibody therapy. Transplant Proc 1988; 20: 202–208.PubMedGoogle Scholar
  71. 71.
    Tellides G, Dallman MJ and Morris PJ. NDS 61, a new monoclonal antibody to the rat interleukin 2 receptor (IL-2R) induces long term allograft survival. British Journal of Surgery 1987; 74: 1145–1146.Google Scholar
  72. 72.
    Reed MH, Shapiro ME, Strom TB et al. Prolongation of primate renal allograft survival by anti-Tac, an anti-human IL-2 receptor monoclonal antibody. Transplantation 1989; 47: 55–59.PubMedCrossRefGoogle Scholar
  73. 73.
    Brown PS, Jr., Parenteau GL, Dirbas FM et al. Anti-Tac-H, a humanized antibody to the interleukin 2 receptor, prolongs primate cardiac allograft survival. Proc Nad Acad Sci USA 1991; 88: 2663–2667.CrossRefGoogle Scholar
  74. 74.
    Tighe H, Friend PJ and Collier SJ. Delayed allograft rejection in primates treated with anti-IL-2 receptor monoclonal antibody Campath-6. Transplantation 1988; 45: 226–228.PubMedCrossRefGoogle Scholar
  75. 75.
    Kupiec-Weglinski JW, Diamantstein T, Tilney NL and Strom TB. Therapy with monoclonal antibody to interleukin 2 receptor spares suppressor T cells and prevents or reverses acute allograft rejection in rats. Proc Natl Acad Sci USA 1986; 83: 2624–2627.PubMedCrossRefGoogle Scholar
  76. 76.
    Kirkman RL, Barrett LV, Galuton GN et al. Administration of an anti-interleukin 2 receptor monoclonal antibody prolongs allograft survival in mice. J Exp Med 1985; 162: 358–362.PubMedCrossRefGoogle Scholar
  77. 77.
    Tanaka K, Hancock W, Osawa H et al. Mechanism of action of anti-IL-2R monoclonal antibodies: ART-18 prolongs cardiac allograft survival in rats by elimination of IL-2R+ mononuclear cells. J Immunol 1989; 143: 2873–2879.PubMedGoogle Scholar
  78. 78.
    Kupiec-Weglinski JW, Tilney NL, Stunkel KG et al. Agonistic and antagonistic interactions of anti-interleukin 2 receptor monoclonal antibodies in rat recipients of cardiac allografts. Transplantation 1989; 47: 11–16.PubMedCrossRefGoogle Scholar
  79. 79.
    Wood MJA, Sloan DJ, Dallman MJ and Charlton HM. Specific tolerance to neural allografts induced with an antibody to the interleukin 2 receptor. J Exp Med 1993; 177: 597–603.PubMedCrossRefGoogle Scholar
  80. 80.
    Ueda H, Hancock WW, Cheung YC, Tanaka K, Kupiec-Weglinski JW and Tilney NL. Differential effects of interleukin 2 receptortargeted therapy on heart and kidney allografts in rats. Depression of effectiveness of ART-18 monoclonal antibody treatment by uremia. Transplantation 1990; 49: 1124–1129.PubMedCrossRefGoogle Scholar
  81. 81.
    Tellides G, Dallman MJ, Kupiec-Weglinski JW, Diamantstein T and Morris PJ. Functional blocking of the interleukin-2 receptor (IL-2R) may be important in the efficacy of IL-2R antibody therapy. Transplant Proc 1987; 19: 4231–4233.PubMedGoogle Scholar
  82. 82.
    Jacques Y, Paineau J, Chevalier S, Le Mauff B and Soulillou JP. A study on OX39, a murine anti-rat interleukin 2 receptor antibody: a report on receptor binding and effects on allograft survival. Transplant Int 1988; 1: 58–63.Google Scholar
  83. 83.
    Ishizaka ST and Stutman O. Analysis by limiting dilution of interleukin-2 producing T cells in murine ontogeny. Eur J Immunol 1983; 13: 936–942.PubMedCrossRefGoogle Scholar
  84. 84.
    Malkovsky M, Medawar PB, Thatcher DR et al. Acquired immunological tolerance of foreign cells is impaired by recombinant interleukin 2 or vitamin A acetate. Proc Natl Acad Sci USA 1985; 82: 536–538.PubMedCrossRefGoogle Scholar
  85. 85.
    Malkovsky M and Medawar PB. Is immunological tolerance (non-responsive) a consequence of interleukin 2 deficit during the recognition of antigen? Immunol Today 1984; 5: 340–343.CrossRefGoogle Scholar
  86. 86.
    Colizzi V. In vivo and in vitro administration of interleukin-2 containing preparation reverses T-cell unresponsiveness in Mycobacterium bovis BCG-infected mice. Infect Immun 1984; 45: 25–28.PubMedGoogle Scholar
  87. 87.
    Dallman MJ, Shiho H, Page TH, Wood KJ and Morris PJ. Peripheral tolerance to alloantigen results from altered regulation of the interleukin 2 pathway. J Exp Med 1991; 173: 79–87.PubMedCrossRefGoogle Scholar
  88. 88.
    Schwartz RH. A cell culture model for T lymphocyte clonal anergy. Science 1990; 248: 1349–1356.PubMedCrossRefGoogle Scholar
  89. 89.
    Kang SM, Beverly B, Tran AC, Brorson K, Schwartz RH and Lenardo MJ. Transactivation by AP-1 is a molecular target of T cell clonal anergy. Science 1992; 257: 1134–1138.PubMedCrossRefGoogle Scholar
  90. 90.
    Alters SE, Shizuru JA, Ackerman J, Grossman D, Seydl KB and Fathman CG. Anti-CD4 mediates clonal anergy during transplantation tolerance induction. J Exp Med 1991; 173: 491–494.PubMedCrossRefGoogle Scholar
  91. 91.
    Dallman MJ, Wood KJ, Hamano K et al. Cytokines and peripheral tolerance to alloantigen. Immunol Rev 1993; 133: 5–18.PubMedCrossRefGoogle Scholar
  92. 92.
    Boussiotis VA, Barber DL, Nakarai T et al. Prevention of T cell energy by signalling through the gamma c chain of the IL-2 receptor. Science 1994; 266: 1039–1042.PubMedCrossRefGoogle Scholar
  93. 93.
    Hahn HJ, Kuttler B, Kloting I, Dunger A, Besch W and Diamantstein T. Extended survival of MHC-identical allogeneic islet grafts in diabetic BB rats—the effect of an interleukin 2 receptortargeted immunotherapy. Transplantation 1992; 54: 555–558.PubMedCrossRefGoogle Scholar
  94. 94.
    Cantarovich D, Le Mauff B, Hourmant M et al. Anti-interleukin 2 receptor monoclonal antibody in the treatment of ongoing acute rejection episodes of human kidney graft-a pilot study. Transplantation 1989; 47: 454–457.PubMedCrossRefGoogle Scholar
  95. 95.
    Carl S, Wiesel M, Daniel V and Staehler G. Effect of the anti-IL-2 receptor monoclonal antibody BT—563 in treatment of acute interstitial renal rejection. Transplant Proc 1995; 27: 854.PubMedGoogle Scholar
  96. 96.
    Soulillou JP, Cantarovich D, Le Mauff B et al. Randomised controlled trial of a monoclonal antibody against the interleukin-2 receptor (33B3.1) as compared with rabbit antithymocyte globulin for prophylaxis against rejection of renal allografts. N Engl J Med 1990; 322: 1175–1182.PubMedCrossRefGoogle Scholar
  97. 97.
    Kriaa F, Hiesse C, Alard P et al. Prophylactic use of the anti-IL-2 receptor monoclonal antibody LO-Tact-1 in cadaveric renal transplantation: results of a randomized study. Transplant Proc 1993; 25: 817–819.PubMedGoogle Scholar
  98. 98.
    Cantarovich D, Le Mauff B, Hourmant M et al. Prevention of acute rejection episodes with an anti-interleukin 2 receptor monoclonal antibody. I. Results after combined pancreas and kidney transplantation. Transplantation 1994; 57: 198–203.PubMedCrossRefGoogle Scholar
  99. 99.
    Hourmant M, Le Mauff B, Cantarovich D et al. Prevention of acute rejection episodes with an anti-interleukin 2 receptor monoclonal antibody. II. Results after a second kidney transplantation. Transplantation 1994; 57: 204–207.PubMedCrossRefGoogle Scholar
  100. 100.
    Kirkman RL, Shapiro ME, Carpenter CB et al. A randomised prospective trial of anti-Tac monoclonal antibody in human renal transplantation. Transplantation 1991; 51: 107–113.PubMedCrossRefGoogle Scholar
  101. 101.
    Amlot PL, Rawlings E, Fernando ON et al. Prolonged action of a chimeric IL-2 receptor (CD25) monoclonal antibody used in cadaveric renal transplantation. Transplantation 1995; (in press).Google Scholar
  102. 102.
    Cantarovich D, Le Mauff B, Hourmant M et al. Prophylactic use of a monoclonal antibody (33B3.1) directed against interleukin 2 receptor following human renal transplantation. American Journal of Kidney Diseases 1988; XI: 101–106.Google Scholar
  103. 103.
    Soulillou JP, Peyronnet P, Le Mauff B et al. Prevention of rejection of kidney transplants by monoclonal antibody directed against interleukin 2. Lancet 1987; 1: 1339–1342.PubMedCrossRefGoogle Scholar
  104. 104.
    van Gelder T, Kroes LCM, Mulder A, Gratama J and Weimar W. A living-related kidney donor as the source of a nearly fatal primary Epstein-Barr virus infection following transplantation. Transplantation 1994; 58: 852–855.PubMedGoogle Scholar
  105. 105.
    Reding R, Vraux H, de Ville de Goyet J et al. Monoclonal antibodies in prophylactic immunosuppression after liver transplantation. A randomized controlled trial comparing OKT3 and anti-IL-2 receptor monoclonal antibody LO-Tact-1. Transplantation 1993; 55: 534–541.PubMedCrossRefGoogle Scholar
  106. 106.
    Otto G, Thies J, Kraus T et al. Monoclonal anti-CD25 for acute rejection after liver transplantation [letter]. Lancet 1991; 338: 195PubMedCrossRefGoogle Scholar
  107. 107.
    Neuhaus P, Bechstein WO, Blumhardt G et al. Comparison of quadruple immunosuppression after liver transplantation with ATG or IL-2 receptor antibody. Transplantation 1993; 55: 1320–1327.PubMedCrossRefGoogle Scholar
  108. 108.
    Herve P, Racadot E, Wendling D et al. Use of monoclonal antibodies in vivo as a therapeutic strategy for alloimmune or autoimmune reactivity: the Besancon experience. Immunol Rev 1992; 129: 31–55.PubMedCrossRefGoogle Scholar
  109. 109.
    Herbelin C, Stephan JL, Donadieu J et al. Treatment of steroidresistant acute graft-versus-host disease with an anti-IL-2-receptor monoclonal antibody (BT 563) in children who received T cell-depleted, partially matched, related bone marrow transplants. Bone Marrow Transplantation 1994; 13: 563–569.PubMedGoogle Scholar
  110. 110.
    Cuthbert RJ, Phillips GL, Barnett MJ et al. Anti-interleukin-2 receptor monoclonal antibody (BT 563) in the treatment of severe acute GVHD refractory to systemic corticosteroid therapy. Bone Marrow Transplantation 1992; 10: 451–455.PubMedGoogle Scholar
  111. 111.
    Anasetti C, Hansen JA, Waldmann TA et al. Treatment of acute graft-versus-host disease with humanized anti-Tac:an antibody that binds to the interleukin-2 receptor. Blood 1994; 84: 1320–1327.PubMedGoogle Scholar
  112. 112.
    Anasetti C, Martin PJ, Hansen JA et al. A phase I-II study evaluating the murine anti-IL-2 receptor antibody 2A3 for treatment of acute graft-versus-host disease. Transplantation 1990; 50: 49–54.PubMedCrossRefGoogle Scholar
  113. 113.
    Ferrant A, Latinne D, Bazin H et al. Prophylaxis of graft-versus-host disease in identical sibling donor BMT by anti-IL-2 receptor monoclonal antibody LO-Tact-1. Blood 1995; (in press).Google Scholar
  114. 114.
    Blaise D, Olive D, Michallet M et al. Impairment of leukemia-free survival by addition of interleukin-2-receptor antibody to standard graft-versus-host-prophylaxis. Lancet 1995; 345: 1144–46.PubMedCrossRefGoogle Scholar
  115. 115.
    Anasetti C, Martin PJ, Storb R et al. Prophylaxis of graft-versus-host disease by administration of the murine anti-IL-2 receptor antibody 2A3. Bone Marrow Transplantation 1991; 7: 375–381.PubMedGoogle Scholar
  116. 116.
    Laufer G, Kukutschki W, Haan A et al. Prospective randomised trial of antithymocyte globulin vs. monoclonal IL-2 receptor antibody as early immunoprophylaxis after cardiac transplantation. 1993. (UnPub).Google Scholar
  117. 117.
    van Gelder T, Balk AH, Mochtar B and Weimar W. Reversal of graft rejection with monoclonal anti-interleukin-2 receptor [letter]. Lancet 1992; 339: 873.PubMedCrossRefGoogle Scholar
  118. 118.
    Janszen M, Buck D, Maino VC. Functional and molecular properties of CD25 monoclonal antibodies. Keukocyte Typing IV, ed Knapp W, Dorken B, Gilks WR et al. Oxford: Oxford University Press 1989; 403.Google Scholar
  119. 119.
    Wong JT, Schott E, Sabga EM, Kielpinski GG and Colvin RB. Immunogenic epitopes of the p55 chain of the IL-2 receptor. Transplantation 1990; 49: 587–596.PubMedCrossRefGoogle Scholar
  120. 120.
    Friend PJ, Tighe H, Waldmann H et al. Monoclonal antibodies that recognise activated human lymphocytes-experimental and clinical studies. Transplant Proc 1988; XX: 265–266.Google Scholar
  121. 121.
    Rose B, Gillespie A, Wunderlich D et al. A chimeric mouse/human anti-IL-2 receptor antibody with enhanced biological activities. Mol Immunol 1992; 29: 131–144.PubMedCrossRefGoogle Scholar
  122. 122.
    Vandevyver C, Steukers M, Lambrechts J, Heyligen H and Raus J. Development and functional characterization of a murine/human chimeric antibody with specificity for the human interleukin-2 receptor. Mol Immunol 1993; 30: 865–876.PubMedCrossRefGoogle Scholar
  123. 123.
    Kaluza B, Lenz H, Russmann E et al. Synthesis and functional characterization of a recombinant monoclonal antibody directed against the alpha-chain of the human interleukin-2 receptor. Gene 1991; 107: 297–305.PubMedCrossRefGoogle Scholar
  124. 124.
    Weissenhorn W, Scheuer W, Kaluza B et al. Combinatorial functions of two chimeric antibodies directed to human CD4 and one directed to the alpha-chain of the human interleukin-2 receptor. Gene 1992; 121: 271–278.PubMedCrossRefGoogle Scholar
  125. 125.
    Queen C, Schneider WP, Selick HE et al. A humanised antibody that binds to the interleukin 2 receptor. Proc Natl Acad Sci USA 1989; 86: 10029.PubMedCrossRefGoogle Scholar
  126. 126.
    Nakatani T, Lone YC, Yamakawa J et al. Humanization of mouse anti-human IL-2 receptor antibody B-B10. Protein Engineering 1994; 7: 435–443.PubMedCrossRefGoogle Scholar
  127. 127.
    Kaluza B, Betzl G, Shao H, Diamantstein T and Weidle UH. A general method for chimerization of monoclonal antibodies by inverse polymerase chain reaction which conserves authentic N-terminal sequences. Gene 1992; 122: 321–328.PubMedCrossRefGoogle Scholar
  128. 128.
    Hakimi J, Ha VC, Lin P et al. Humanised Mikßl, a humanised antibody to the IL-2 receptor β-chain that acts synergistically with humanised anti-TAC. J Immunol 1993; 151: 1075–1085.PubMedGoogle Scholar
  129. 129.
    Kelley VE, Bacha P, Pankewycz OG, Nichols JC, Murphy JR and Strom TB. Interleukin 2-diptheria toxin fusion protein can abolish cell-mediated immunity in vivo. Proc Natl Acad Sci USA 1988; 85: 3980–3984.PubMedCrossRefGoogle Scholar
  130. 130.
    Kirkman RL, Bacha P, Barrett LV, Forte SE, Murphy JR and Strom TB. Prolongation of cardiac allograft survival in murine recipients treated with a diptheria toxin-related interleukin-2 fusion protein. Transplantation 1989; 47: 327–330.PubMedCrossRefGoogle Scholar
  131. 131.
    LeMaistre CF, Meneghetti CM, Rosenblum MG et al. Phase I trial of an interleukin-2 (IL-2) fusion toxin (DAB486) in haematological malignancies expressing the IL-2 receptor. Blood 1992; 79: 2547–2554.PubMedGoogle Scholar
  132. 132.
    Vie H, Gauthier T, Breathnach R et al. Human fusion proteins between interleukin 2 and IgM heavy chain are cytotoxic for cells expressing the interleukin 2 receptor. Proc Natl Acad Sci USA 1992; 89: 11337–11341.PubMedCrossRefGoogle Scholar
  133. 133.
    Takeshita T, Goto Y, Tada K, Nagata K, Asao H and Sugamura K. Monoclonal antibody defining a molecule possibly identical to the p75 subunit of interleukin 2 receptor. J Exp Med 1989; 169: 1323–1332.PubMedCrossRefGoogle Scholar
  134. 134.
    Nakamura Y, Inamoto T, Sugie K et al. Mitogenicity and down-regulation of high-affinity interleukin 2 receptor by YTA-1 and YTA-2 monoclonal antibodies that recognise 75-kDa molecules on human large granular lymphocytes. Proc Natl Acad Sci USA 1989; 86: 1318–1322.PubMedCrossRefGoogle Scholar
  135. 135.
    Ohbo K, Takeshita T, Asao H et al. Monoclonal antibodies defining distinct epitopes of the human IL-2 receptor beta chain and their differential effects on IL-2 responses. J Immunol Methods 1991; 142: 61–72.PubMedCrossRefGoogle Scholar
  136. 136.
    Francois C, Boeffard F, Kaluza B, Weidle UH and Jacques Y. Construction of a bispecific antibody reacting with the alpha-and beta-chains of the human IL-2 receptor. High affinity cross-linking and high anti-proliferative efficiency. J Immunol 1993; 150: 4610–4619.PubMedGoogle Scholar
  137. 137.
    Gnarra JR, Otani H, Wang MG, McBride OW, Sharon M and Leonard WJ. Human interleukin 2 receptor beta-chain genexhromosomal localization and identification of 5’ regulatory sequences. Proc Natl Acad Sci USA 1990; 87: 3440–3444.PubMedCrossRefGoogle Scholar
  138. 138.
    Shibuya H, Yoneyama M, Nakamura Y et al. The human interleukin-2 receptor β chain gene:genomic organisation, promoter analysis and chromosomal assignment. Nucleic Acids Research 1990; 18: 3697–3703.PubMedCrossRefGoogle Scholar
  139. 139.
    Arima N, Karnio M, Imada K et al. Pseudo-high affinity interleukin 2 (IL-2) receptor lacks the third component that is essential for functional IL-2 binding and signaling. J Exp Med 1992; 176: 1265–1272.PubMedCrossRefGoogle Scholar
  140. 140.
    Cosman D, Lyman SD, Idzerda RL et al. A new cytokine receptor superfamily. Trends in Biochemical Science 1990; 15: 265–269.CrossRefGoogle Scholar
  141. 141.
    Ohashi Y, Takeshita T, Nagata K, Mori S and Sugamura K. Differential expression of the IL-2 receptor subunits, p55 and p75 on various populations of primary peripheral blood mononuclear cells. J Immunol 1989; 143: 3548–3555.PubMedGoogle Scholar
  142. 142.
    Yagita H, Nakata M, Azuma A et al. Activation of peripheral blood T cells via the p75 interleukin 2 receptor. J Exp Med 1989; 170: 1445–1450.PubMedCrossRefGoogle Scholar
  143. 143.
    Djeu JY, Liu JH, Wei S et al. Function associated with IL-2 receptor-b on human neutrophils. Mechanism of activation of antifungal activity against Candida albicans by IL-2. J Immunol 1993; 150: 960–970.PubMedGoogle Scholar
  144. 144.
    Ferrara JLM, Marion A, McIntyre JF, Murphy GF and Burakoff SJ. Amelioration of acute graft vs host disease due to minor histocompatibility antigens by in vivo administration of anti-interleukin 2 receptor antibody. J Immunol 1986; 137: 1874–1877.PubMedGoogle Scholar
  145. 145.
    Volk H, Brocke S, Osawa H and Diamantstein T. Effects of in-vivo administration of a monoclonal antibody specific for the interleukin-2 receptor on the acute graft-versus-host reaction in mice. Clin Exp Immunol 1986; 66: 126–131.PubMedGoogle Scholar
  146. 146.
    Kupiec-Weglinski JW, Sablinski T, Hancock WW, Di Stefano R, Mariani G and Tilney NL. Modulation of accelerated rejection of cardiac allografts in sensitized rats by anti-interleukin 2 receptor monoclonal antibody and cyclosporine therapy. Transplantation 1991; 51: 300–305.PubMedCrossRefGoogle Scholar
  147. 147.
    Ueda H, Hancock WW, Cheung Y, Diamantstein T, Tilney NL and Kupiec-Weglinski JW. The mechanism of synergistic interaction between anti-interleukin 2 receptor monoclonal antibody and cyclosporine therapy in rat recipients of organ allografts. Transplantation 1990; 50: 545–550.PubMedCrossRefGoogle Scholar
  148. 148.
    Hancock WW, DiStefano R, Braun P, Schweizer RT, Tilney NL and Kupiec-Weglinski JW. Cyclosporine and anti-interleukin 2 receptor monoclonal antibody therapy suppress accelerated rejection of rat cardiac allografts through different effector mechanisms. Transplantation 1990; 49: 416–421.PubMedCrossRefGoogle Scholar
  149. 149.
    van Gelder T, Zietse R, Yzermans JNM, Vaessen LMB, Mulder AH and Weimar W. Monoclonal anti-IL-2 receptor antibody (BT563) prevents early rejection after kidney transplantation. A double blind, placebo controlled trial. Transplant Proc 1995; (in press).Google Scholar
  150. 150.
    Hiesse C, Kriaa F, Alard P et al. Prophylactic use of the IL-2 receptor-specific monoclonal antibody LO-Tact-1 with cyclosporin A and steroids in renal transplantation. Transplant Int 1992; 5: S444–S447.Google Scholar
  151. 151.
    Friend PJ, Waldmann H, Cobbold S et al. The anti-IL-2 receptor monoclonal antibody YTH-906 in liver transplantation. Transplant Proc 1991; 23: 1390–1392.PubMedGoogle Scholar
  152. 152.
    Herve P, Wijdenes J, Bergerat JP et al. Treatment of corticosteroid resistant acute-graft-versus-host disease by in vivo administration of anti-interleukin-2 receptor monoclonal antibody (B-B10). Blood 1990; 75: 1017–1023.PubMedGoogle Scholar
  153. 153.
    Tiley C, Powles R, Teo CP, Treleaven J, Findlay M and Hewetson M. Treatment of acute graft versus host disease with a murine monoclonal antibody to the IL-2 receptor. Bone Marrow Transplantation 1991; 7 Suppl 2: 151PubMedGoogle Scholar
  154. 154.
    Belanger C, Esperou-Bourdeau H, Bordigoni P et al. Use of an anti-interleukin-2 receptor monoclonal antibody for GVHD prophylaxis in unrelated donor BMT. Bone Marrow Transplantation 1993; 11: 293–297.PubMedGoogle Scholar
  155. 155.
    Burdach S, Mauz C, Hanenberg H et al. Prevention of acute and chronic graft versus host disease (GVHD) with prolonged p55 IL2 receptor antibody therapy in bone marrow transplant recipients at high risk for GVHD. Blood 1995; (in press).Google Scholar
  156. 156.
    Beliard R. Selection d’un anticorps monoclonal anti-recepteur de l’interleukine-2 humaine en vue d’une utilisation therapeutique. 1991; 60-76. (Abstract).Google Scholar
  157. 157.
    Engert A, Martin G, Amlot PL, Wijdenes J, Diehl V and Thorpe PE. Immunotoxins constructed with anti-CD25 monoclonal antibodies and deglycosylated ricin A-chain have potent anti-tumour effects against human Hodgkin cells in vitro and solid Hodgkin tumours in mice. Int J Cancer 1991; 49: 450–456.PubMedCrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media Dordrecht 1995

Authors and Affiliations

  • Peter L. Amlot

There are no affiliations available

Personalised recommendations